Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2007

CEL-SCI Gets $15M for Cancer Therapy Manufacturing Facility

  • BioProperties, a real estate firm specialized in the biomedical sector, committed $15 million to CEL-SCI to acquire and build out a manufacturing facility for the company’s cancer product, according to a letter of intent. Multikine® was recently approved to enter Phase III studies for the treatment of head and neck cancer.

    The facility is expected to cost about $12–14 million, to be paid through a long-term lease agreement. "We will be able to produce our drug Multikine in our own CGMP facility for Phase III trials as well as for sale once marketing approval is granted,” states Geert Kersten, CEO of CEL-SCI.

    “An additional benefit of having this facility,” Kersten adds, “is that during the Phase III study, it may also be used for contract manufacturing work with other biotech companies and/or the U.S. government since it will contain a clean cold-fill suite."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »